Inflammatory markers in Eisenmenger syndrome and their association with clinical outcomes. A cross-sectional comparative study.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Nov 2021
Historique:
received: 15 01 2021
revised: 02 04 2021
accepted: 18 06 2021
pubmed: 26 6 2021
medline: 21 10 2021
entrez: 25 6 2021
Statut: ppublish

Résumé

Inflammation may be an important factor contributing to the progression of Eisenmenger syndrome (ES). The purpose of the current study was to: characterize the inflammatory profile in ES patients and compare measures to reference values for congenital heart disease and pulmonary arterial hypertension (CHD-PAH); and investigate whether inflammatory markers are associated with other clinical markers in ES. Twenty-seven ES patients were prospectively selected and screened for systemic inflammatory markers, including interleukin (IL)-1β, tumor necrosis factor-alpha (TNF-α) and IL-10. Clinical data and echocardiographic parameters were obtained, with concomitant analysis of ventricular function. Functional capacity was assessed using the 6-min walk test (6MWT). Renal function and blood homeostasis were evaluated by the level of blood urea nitrogen (BUN), creatinine, and plasma electrolytes. Patients with ES expressed higher IL-10, IL-1β and TNF-α compared to reference values of patients with CHD-PAH. IL-10 was negatively associated with BUN (r = -0.39,p = 0.07), creatinine (r = -0.35, p = 0.002), sodium (r = -0.45, p = 0.03), and potassium (r = -0.68, p = 0.003). IL-10 was positively associated with bicarbonate (r = 0.45, p = 0.02) and trended toward a positive association with right ventricular fractional area change (RV ES patients exhibit a more severe inflammatory profile compared to reference values for CHD-PAH. Furthermore, inflammatory markers are related to renal dysfunction, right ventricular impairment and poorer functional capacity.

Sections du résumé

BACKGROUND BACKGROUND
Inflammation may be an important factor contributing to the progression of Eisenmenger syndrome (ES). The purpose of the current study was to: characterize the inflammatory profile in ES patients and compare measures to reference values for congenital heart disease and pulmonary arterial hypertension (CHD-PAH); and investigate whether inflammatory markers are associated with other clinical markers in ES.
METHODS METHODS
Twenty-seven ES patients were prospectively selected and screened for systemic inflammatory markers, including interleukin (IL)-1β, tumor necrosis factor-alpha (TNF-α) and IL-10. Clinical data and echocardiographic parameters were obtained, with concomitant analysis of ventricular function. Functional capacity was assessed using the 6-min walk test (6MWT). Renal function and blood homeostasis were evaluated by the level of blood urea nitrogen (BUN), creatinine, and plasma electrolytes.
RESULTS RESULTS
Patients with ES expressed higher IL-10, IL-1β and TNF-α compared to reference values of patients with CHD-PAH. IL-10 was negatively associated with BUN (r = -0.39,p = 0.07), creatinine (r = -0.35, p = 0.002), sodium (r = -0.45, p = 0.03), and potassium (r = -0.68, p = 0.003). IL-10 was positively associated with bicarbonate (r = 0.45, p = 0.02) and trended toward a positive association with right ventricular fractional area change (RV
CONCLUSION CONCLUSIONS
ES patients exhibit a more severe inflammatory profile compared to reference values for CHD-PAH. Furthermore, inflammatory markers are related to renal dysfunction, right ventricular impairment and poorer functional capacity.

Identifiants

pubmed: 34171450
pii: S0167-5273(21)01037-8
doi: 10.1016/j.ijcard.2021.06.039
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-38

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Laion R A Gonzaga (LRA)

Cardiology Postgraduate Program, Federal University of Sao Paulo, Rua Napoleão de Barros, 715 - 04024002, Vila Clementino, Sao Paulo, Brazil.

Walter J Gomes (WJ)

Cardiology and Cardiovascular Surgery Disciplines, Sao Paulo Hospital, Federal University of Sao Paulo, Rua Napoleão de Barros, 715, 3 andar - 04024002, Vila Clementino, Sao Paulo, Brazil.

Isadora S Rocco (IS)

Cardiology Postgraduate Program, Federal University of Sao Paulo, Rua Napoleão de Barros, 715 - 04024002, Vila Clementino, Sao Paulo, Brazil.

Bruna C Matos-Garcia (BC)

Cardiology Postgraduate Program, Federal University of Sao Paulo, Rua Napoleão de Barros, 715 - 04024002, Vila Clementino, Sao Paulo, Brazil.

Caroline Bublitz (C)

Cardiology and Cardiovascular Surgery Disciplines, Sao Paulo Hospital, Federal University of Sao Paulo, Rua Napoleão de Barros, 715, 3 andar - 04024002, Vila Clementino, Sao Paulo, Brazil.

Marcela Viceconte (M)

Cardiology Postgraduate Program, Federal University of Sao Paulo, Rua Napoleão de Barros, 715 - 04024002, Vila Clementino, Sao Paulo, Brazil.

Solange B Tatani (SB)

Cardiology and Cardiovascular Surgery Disciplines, Sao Paulo Hospital, Federal University of Sao Paulo, Rua Napoleão de Barros, 715, 3 andar - 04024002, Vila Clementino, Sao Paulo, Brazil.

Vinicius B Santos (VB)

Cardiology and Cardiovascular Surgery Disciplines, Sao Paulo Hospital, Federal University of Sao Paulo, Rua Napoleão de Barros, 715, 3 andar - 04024002, Vila Clementino, Sao Paulo, Brazil.

Célia M C Silva (CMC)

Cardiology and Cardiovascular Surgery Disciplines, Sao Paulo Hospital, Federal University of Sao Paulo, Rua Napoleão de Barros, 715, 3 andar - 04024002, Vila Clementino, Sao Paulo, Brazil.

Robert Tulloh (R)

Department of Congenital Heart Disease, Bristol Heart Institute, Bristol BS2 8BJ, United Kingdom.

Ross Arena (R)

Department of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago, Taylor Street, 454 AHSB, Chicago, IL 60612, USA.

Solange Guizilini (S)

Cardiology Postgraduate Program, Federal University of Sao Paulo, Rua Napoleão de Barros, 715 - 04024002, Vila Clementino, Sao Paulo, Brazil; Department of Human Motion Sciences, Physical Therapy School, Federal University of Sao Paulo, Rua Silva Jardim, Edifício Central 136, 11015-020 Santos/SP, Brazil. Electronic address: sguizilini@unifesp.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH